Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease

Completed · Phase 2

Conditions studied: Graft Versus Host Disease

In brief

RATIONALE: Pentostatin may be effective in treating chronic graft-versus-host disease by stopping the immune system from rejecting donor stem cells or donor white blood cells. PURPOSE: This phase II trial is studying how well pentostatin works in treating patients with chronic graft-versus-host disease that is refractory (not responsive) to treatment with steroids.

Key facts

Study ID
NCT00074035
Run by
Alliance for Clinical Trials in Oncology
People needed
39
Starts
2003-12-01
Expected to finish
2014-11-01
Last updated by the study team
2021-11-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.